Navigation Links
CardioMEMS Completes CHAMPION Clinical Trial Study
Date:6/1/2010

get='_blank' href="http://www.cardiomems.com/">www.cardiomems.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS is a registered trademark of CardioMEMS, Inc.


'/>"/>
SOURCE CardioMEMS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Brittenford Systems, a ... and other growing businesses across the United States, has announced that it has ... the fifth consecutive year. , Based on company revenue and number of employees, ...
(Date:6/29/2015)... Church, VA (PRWEB) , ... June 29, 2015 ... ... Optimizing Interaction with Medical Devices , **FDAnews Webinar**, July 16, 2015 — 1:30 ... manufacturers to help ensure the application of human factors engineering to the design ...
(Date:6/29/2015)... ... ... across the country give their coworkers and families gifts all the time. From holiday exchanges ... often do coworkers donate “life” to the husband of a coworker? For one VA employee, ... told me her husband was on a donor list,” Glenshaw resident Kathi Dahl said. “I ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two multicounty ... C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New Jersey’s ... Conference is to be convened on Thursday, July 23rd at 12:00 p.m. (In ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, has ... and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief Financial ...
Breaking Medicine News(10 mins):Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3
... a bewildering array of regulatory DNA sequences interacting with a ... which genes are active when and where. Understanding how ... past decades but we are now starting to make significant ... how the entire complexity evolves to give differences in the ...
... giving up smoking after a programme involving sending motivational and ... months. , The findings of the txt2stop trial, which was ... and funded by the Medical Research Council, are published in ... innovative approach to the deadly problem of smoking, which is ...
... Current or heavy smokers who were screened with low-dose spiral ... deaths from lung cancer than did those who were screened ... clinical trial that involved more than 53,000 people. The ... in individuals at high risk of developing lung cancer to ...
... 29, 2011) A new treatment option may soon ... published in the July issue of The Journal ... that combined positron emission tomography and X-ray computed tomography ... refractory or relapsed high-risk neuroblastoma for treatment with a ...
... News) -- A new study reveals that 90 percent of ... started smoking, drinking or using drugs before they were 18 ... Americans who began using any addictive substance before age 18 ... using an addictive substance when they were 21 or older. ...
... cancer has provided the most comprehensive and integrated view of ... adenocarcinoma tumors from 500 patients were examined by The Cancer ... the June 30, 2011, issue of Nature . ... cancer, accounting for about 85 percent of all ovarian cancer ...
Cached Medicine News:Health News:Many a mickle makes a muckle: How changes in animals' size and shape arise 2Health News:Text message support for smokers doubles quit rates 2Health News:Screening with low-dose spiral CT scanning reduces lung cancer deaths by 20 percent 2Health News:Screening with low-dose spiral CT scanning reduces lung cancer deaths by 20 percent 3Health News:New therapy for childhood neuroblastoma proves feasible and safe 2Health News:Addiction Starts Early in American Society, Report Finds 2Health News:Addiction Starts Early in American Society, Report Finds 3Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 2Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: